TY  - JOUR
A1  - Olmer, Ruth
A1  - Engels, Lena
A1  - Usman, Abdulai
A1  - Menke, Sandra
A1  - Malik, Muhammad Nasir Hayat
A1  - Pessler, Frank
A1  - Goehring, Gudrun
A1  - Bornhorst, Dorothee
A1  - Bolten, Svenja
A1  - Abdelilah-Seyfried, Salim
A1  - Scheper, Thomas
A1  - Kempf, Henning
A1  - Zweigerdt, Robert
A1  - Martin, Ulrich
T1  - Differentiation of Human Pluripotent Stem Cells into Functional Endothelial Cells in Scalable Suspension Culture
JF  - Stem Cell Reports
N2  - Endothelial cells (ECs) are involved in a variety of cellular responses. As multifunctional components of vascular structures, endothelial (progenitor) cells have been utilized in cellular therapies and are required as an important cellular component of engineered tissue constructs and in vitro disease models. Although primary ECs from different sources are readily isolated and expanded, cell quantity and quality in terms of functionality and karyotype stability is limited. ECs derived from human induced pluripotent stem cells (hiPSCs) represent an alternative and potentially superior cell source, but traditional culture approaches and 2D differentiation protocols hardly allow for production of large cell numbers. Aiming at the production of ECs, we have developed a robust approach for efficient endothelial differentiation of hiPSCs in scalable suspension culture. The established protocol results in relevant numbers of ECs for regenerative approaches and industrial applications that show in vitro proliferation capacity and a high degree of chromosomal stability.
KW  - virus infection
KW  - progenitor cells
KW  - in vitro
KW  - telomere dysfunction
KW  - cord blood
KW  - cardiomyogenic differentiation
KW  - angiogenesis
KW  - efficient
KW  - aberrations
KW  - expression
Y1  - 2017
U6  - https://doi.org/10.1016/j.stemcr.2018.03.017
SN  - 2213-6711
VL  - 10
IS  - 5
PB  - Springer
CY  - New York
ER  - 
TY  - JOUR
A1  - Braune, Steffen
A1  - Latour, Robert A.
A1  - Reinthaler, Markus
A1  - Landmesser, Ulf
A1  - Lendlein, Andreas
A1  - Jung, Friedrich
T1  - In Vitro Thrombogenicity Testing of Biomaterials
JF  - Advanced healthcare materials
N2  - The short- and long-term thrombogenicity of implant materials is still unpredictable, which is a significant challenge for the treatment of cardiovascular diseases. A knowledge-based approach for implementing biofunctions in materials requires a detailed understanding of the medical device in the biological system. In particular, the interplay between material and blood components/cells as well as standardized and commonly acknowledged in vitro test methods allowing a reproducible categorization of the material thrombogenicity requires further attention. Here, the status of in vitro thrombogenicity testing methods for biomaterials is reviewed, particularly taking in view the preparation of test materials and references, the selection and characterization of donors and blood samples, the prerequisites for reproducible approaches and applied test systems. Recent joint approaches in finding common standards for a reproducible testing are summarized and perspectives for a more disease oriented in vitro thrombogenicity testing are discussed.
KW  - biomaterials
KW  - blood tests
KW  - implants
KW  - in vitro
KW  - thrombogenicity
Y1  - 2019
U6  - https://doi.org/10.1002/adhm.201900527
SN  - 2192-2640
SN  - 2192-2659
VL  - 8
IS  - 21
PB  - Wiley
CY  - Hoboken
ER  -